MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$45,144K
(-59.04%↓ Y/Y)
Proceeds from issuance of
common stock under...
$395K
(75.56%↑ Y/Y)
Net cash provided by
investing activities
$37,754K
(104.35%↑ Y/Y)
Net cash provided by
financing activities
$395K
(-98.51%↓ Y/Y)
Canceled cashflow
$7,390K
Net (decrease)
increase in cash, cash...
-$564K
(-103.23%↓ Y/Y)
Canceled cashflow
$38,149K
Share-based compensation
expense
$4,472K
(-17.19%↓ Y/Y)
Deferred revenue
$785K
Depreciation and
amortization
$110K
(100.00%↑ Y/Y)
Other assets
-$20K
(-109.80%↓ Y/Y)
Inventory
-$19K
Purchases of marketable
securities
$7,374K
(-91.93%↓ Y/Y)
Purchases of property and
equipment
$16K
(-95.43%↓ Y/Y)
Net cash used in
operating activities
-$38,713K
(-40.48%↓ Y/Y)
Canceled cashflow
$5,406K
Net loss
-$31,918K
(-8.08%↓ Y/Y)
Accrued liabilities
-$5,110K
(-443.64%↓ Y/Y)
Accounts payable
-$4,281K
(-162.96%↓ Y/Y)
Prepaid expenses and
other current assets
$2,575K
(115.30%↑ Y/Y)
Accretion of discounts and
amortization of premiums on...
$131K
(-93.52%↓ Y/Y)
Accounts receivable, net
$99K
Operating lease
liabilities, net
-$5K
Back
Back
Cash Flow
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)
source: myfinsight.com